Cullinan Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Cambridge, MA
CGEM chart
What traders are saying about $CGEM
Latest postsCullinan Therapeutics, Inc. news
- Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Cullinan Therapeutics to present at major inves...
Pluang ·
- Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Yahoo Finance ·
- Form 8K Cullinan Therapeutics, Inc For: 9 November By Investing.com
Investing.com Canada ·
- Cullinan Therapeutics (CGEM) Reports Positive Phase 1b/2a Data on Velinotamig for Refractory SLE
GuruFocus ·
- Cullinan Therapeutics shares Genrix Phase 1b 2a velinotamig clinical data in SLE
Traders Union ·
- Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
Yahoo Finance ·
- BTIG raises Cullinan Therapeutics price target to $39 on Buy
scanx.trade ·
- Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 4,000 Shares of Stock
MarketBeat ·
- A science chief sells 4,000 Cullinan Therapeutics (CGEM) shares at $12.36 each.
Stock Titan ·
- Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $42
Moomoo ·
- Cullinan Therapeutics, Inc. (CGEM) options chain
Yahoo Finance UK ·
Cullinan Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $0 |
| Net income | -$219.9M | -$167.6M | -$155.1M | $111.2M |
| Diluted EPS | – | – | $-3.69 | $2.38 |
| Total assets (year end) | $448.4M | $621.8M | $484.2M | $561.1M |
| Cash and equivalents (year end) | $88.3M | $83.0M | $98.4M | $156.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Cullinan Therapeutics, Inc.
- Ticker
- CGEM (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1789972
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
Frequently asked questions
What exchange is Cullinan Therapeutics, Inc. listed on?
Cullinan Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CGEM.
What industry is Cullinan Therapeutics, Inc. in?
Cullinan Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Cullinan Therapeutics, Inc. headquartered?
Cullinan Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Cullinan Therapeutics, Inc.'s fiscal year end?
Cullinan Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Cullinan Therapeutics, Inc. report?
Cullinan Therapeutics, Inc. reported $0 in revenue for calendar year 2022, according to its SEC filings.